Evidence map›Paper›PMID 39993806›Full record

ArticleCancer genomics & proteomics

Loss of E-cadherin Activates EGFR-MEK/ERK Signaling, Promoting Cervical Cancer Progression.

Hee Yun, Gwan Hee Han, Daniel J Wee, Doo-Byung Chay, Joon-Yong Chung, Jae-Hoon Kim, Hanbyoul Cho

Abstract read
In one paragraph

Article in Cancer genomics & proteomics. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Polyploidy and Senescence of Cancer Cells: Impact of Cell Fusion.Advances in experimental medicine and biology · 2026
    Review
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Hee Yun *Department of Obstetrics and Gynecology, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea.
Gwan Hee Han *Department of Obstetrics and Gynecology, Sanggye Paik Hospital, Inje University College of Medicine, Seoul, Republic of Korea.
Daniel J WeeDepartment of Chemistry, College of Arts and Sciences, Case Western Reserve University, Cleveland, OH, U.S.A.
Doo-Byung ChayDepartment of Obstetrics and Gynecology, Sahmyook Medical Center, Seoul, Republic of Korea.
Joon-Yong ChungMolecular Imaging Branch, Center for Cancer Research National Cancer Institute, National Institutes of Health, Bethesda, MD, U.S.A.
Jae-Hoon KimDepartment of Obstetrics and Gynecology, Yonsei University College of Medicine, Seoul, Republic of Korea.
Hanbyoul ChoDepartment of Obstetrics and Gynecology, Yonsei University College of Medicine, Seoul, Republic of Korea; hanbyoul@yuhs.ac.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

aimThis study investigated the relationship between E-cadherin down-regulation and enhanced pERK1/2 signaling in cervical cancer, evaluated their combined prognostic impact, and explored potential therapeutic targets. MATERIALS AND

methodsWe analyzed 188 cervical cancer specimens and 300 normal cervical tissue samples using tissue microarray and immunohistochemistry. Small interfering RNA transfection and western blotting were used to study molecular interactions in cervical cancer cell lines.

resultsWe observed a significant inverse correlation between E-cadherin and pERK1/2 expression, as well as poor disease-free survival and overall survival. Additionally, molecular analysis indicated that E-cadherin silencing enhanced ERK signaling and promoted cancer cell proliferation.

conclusionThe findings suggest that E-cadherin and pERK1/2 are crucial biomarkers for cervical cancer prognosis and their interaction provides a potential target for therapeutic interventions. Further studies are recommended to explore these pathways in the clinical setting.

Indexed as

CadherinsMAP Kinase Signaling SystemUterine Cervical NeoplasmsAdultAntigens, CDBiomarkers, TumorCell Line, TumorCell ProliferationDisease ProgressionErbB ReceptorsFemaleGene Expression Regulation, NeoplasticHumansMiddle AgedPrognosisAntigens, CDBiomarkers, TumorCadherinsCDH1 protein, humanEGFR protein, humanErbB Receptorsbiomarkerscervical cancerE-cadherinEGFR-MEK/ERK pathwaypERK1/2 signaling

Identifiers

PMID39993806
PMCPMC11880930

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.